Accurately Predicting CAR-T Toxicity Prior to Patient Treatment Could Help Expand Access to Care
June 26th 2023Jason Westin, MD, FASCP, the director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center, discussed factors that limit patient access to treatment and a potential solution.
Jason Westin, MD, FASCP, on the Potential Impact of Predicting Toxicity for CAR-T Treatment
June 24th 2023The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.